Jon S. Brazier

What is he best known for?

The fields of study he is best known for:

• Bacteria
• Gene
• Antibiotics

His main research concerns Clostridium difficile, Microbiology, Genetics, Genotype and Outbreak. In general Clostridium difficile study, his work on Clostridium difficile toxin A often relates to the realm of Disease prevention, thereby connecting several areas of interest. His Microbiology research is multidisciplinary, incorporating elements of Internal medicine and Restriction fragment length polymorphism, Polymerase chain reaction.

His research investigates the connection between Outbreak and topics such as Environmental health that intersect with problems in Relapse rate and Disease. Jon S. Brazier has included themes like Spacer DNA and Molecular epidemiology in his Typing study. His Clostridium difficile toxin B study which covers Enterotoxin that intersects with Pulsed-field gel electrophoresis.

His most cited work include:

• Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe (1244 citations)
• Clostridium difficile infection in Europe: a hospital-based survey (806 citations)
• Emergence and global spread of epidemic healthcare-associated Clostridium difficile. (498 citations)

What are the main themes of his work throughout his whole career to date?

His primary areas of study are Microbiology, Clostridium difficile, Typing, Outbreak and Polymerase chain reaction. In his study, Gastroenterology and Fusobacterium necrophorum is strongly linked to Internal medicine, which falls under the umbrella field of Microbiology. His Clostridium difficile research is mostly focused on the topic Clostridium difficile toxin A.

His work deals with themes such as Variable number tandem repeat and Pulsed-field gel electrophoresis, which intersect with Typing. The concepts of his Outbreak study are interwoven with issues in Epidemiology, Disease, Public health and Environmental health. His work carried out in the field of Ribotyping brings together such families of science as Molecular epidemiology and Antibiotic resistance.

He most often published in these fields:

• Microbiology (67.89%)
• Clostridium difficile (57.80%)
• Typing (20.18%)

What were the highlights of his more recent work (between 2010-2016)?

• Clostridium difficile (57.80%)
• Microbiology (67.89%)
• Virology (16.51%)

In recent papers he was focusing on the following fields of study:

Jon S. Brazier focuses on Clostridium difficile, Microbiology, Virology, Typing and Pcr ribotyping. The study incorporates disciplines such as Odds ratio, Outbreak, Waterborne pathogen, Ribotyping and Veterinary medicine in addition to Clostridium difficile. His Microbiology study frequently draws connections to adjacent fields such as Polymerase chain reaction.

His studies in Polymerase chain reaction integrate themes in fields like Clostridium difficile toxin A, Clostridium difficile toxin B and Fusobacterium necrophorum. His biological study spans a wide range of topics, including Evolutionary biology, Ciprofloxacin, Metronidazole, Moxifloxacin and Vancomycin. His research in Typing intersects with topics in Variable number tandem repeat and Genotype.

Between 2010 and 2016, his most popular works were:

• Clostridium difficile infection in Europe: a hospital-based survey (806 citations)
• Emergence and global spread of epidemic healthcare-associated Clostridium difficile. (498 citations)
• New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. (56 citations)

In his most recent research, the most cited papers focused on:

• Bacteria
• Gene
• Antibiotics

Jon S. Brazier mainly investigates Clostridium difficile, Virology, Polymerase chain reaction, Gene and Clostridium difficile toxin A. He interconnects Global population and Comorbidity in the investigation of issues within Clostridium difficile. His Global population study combines topics in areas such as Transmission, Phylogenetics and Outbreak.

His studies deal with areas such as Bezlotoxumab, Incidence and Intensive care medicine as well as Comorbidity. His Polymerase chain reaction research incorporates themes from Clostridium difficile toxin B and Toxin, Microbiology. His Disease prevention research spans across into subjects like Enterocolitis, Hospital based and Odds ratio.